Skip to content
value.today

BI02 Medical, Inc.

🇺🇸 San Antonio, Texas, USABiotechnologyFounded 2006
Total raised
$36 M
7 rounds on record
Latest round
$2 M
Mar 2017
First round on record
Sep 2009
Today
Private
No later event on record

Funding rounds

7 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of BI02 Medical, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Mar 2017$2 MNo. 7Under $2 million

BI02 Medical, Inc.: Raise no. 7, Mar 2017

Investors in this round

1 investor had bought by the notice of Mar 31, 2017: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$2 M of $8 M offered; $7 M still to sell
Smallest investment taken
no minimum stated
What was sold
debt, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Up to $1 million
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Texas

People named in the notice

  • Christopher Banas · Executive Officer, Director
  • Luis Angel · Executive Officer, Director
  • Alan Dean · Director
  • John Creecy · Director
  • John Elwood · Director
  • Paul Castella · Director
  • Steven Bailey · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the use of proceeds: “A portion of the proceeds will be used to pay the salaries to be paid to the persons named in response to Item 3 above.”

Signed by Christopher Banas, Chief Executive Officer. Source: SEC Form D, newest notice filed Mar 31, 2017. Read the notice at the SEC.

debt, optionsSEC
Jul 2015$4 MNo. 6$2 to $10 million

BI02 Medical, Inc.: Raise no. 6, Jul 2015

Investors in this round

1 investor had bought by the notice of Jul 10, 2015: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$4 M of $10 M offered; $6 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Up to $1 million
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Texas

People named in the notice

  • Christopher Banas · Executive Officer, Director
  • Luis Angel · Executive Officer, Director
  • Alan Dean · Director
  • John Creecy · Director
  • John Elwood · Director
  • Paul Castella · Director
  • Steven Bailey · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the use of proceeds: “A portion of the proceeds will be used to pay the salaries to be paid to the persons named in response to Item 3 above.”

Signed by Christopher Banas, Chief Executive Officer. Source: SEC Form D, newest notice filed Jul 10, 2015. Read the notice at the SEC.

equitySEC
Feb 2014$6 MNo. 5$2 to $10 million

BI02 Medical, Inc.: Raise no. 5, Feb 2014

Investors in this round

10 investors had bought by the notice of Mar 14, 2014: 10 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$6 M of $8 M offered; $2 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Up to $1 million
Sales commissions
$164,196
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Texas

People named in the notice

  • Christopher Banas · Executive Officer, Director
  • Luis Angel · Executive Officer, Director
  • Alan Dean · Director
  • John Creecy · Director
  • Paul Castella · Director
  • Steven Bailey · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Braymen, Lambert & Noel Securities, Ltd. (CRD 124902) · broker-dealer Braymen, Lambert & Noel Securities, Ltd. (CRD 124902) · San Antonio, TexasSold in TX

Remarks in the notice

  • On the use of proceeds: “A portion of the proceeds will be used to pay the salaries to be paid to the persons named in response to Item 3 above.”

Signed by Christopher Banas, Chief Executive Officer. Source: SEC Form D, newest notice filed Mar 14, 2014. Read the notice at the SEC.

equitySEC
Aug 2012$12 MNo. 4$10 to $50 million

BI02 Medical, Inc.: Raise no. 4, Aug 2012

Investors in this round

30 investors had bought by the notice of Sep 5, 2012: 30 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$12 M of $20 M offered; $8 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
No revenue
Sales commissions
$349,485
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Texas

People named in the notice

  • Christopher Banas · Executive Officer, Director
  • Luis Angel · Executive Officer, Director
  • Paul Castella · Executive Officer, Director
  • Alan Dean · Director
  • John Creecy · Director
  • Steven Bailey · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Karutz Flavin Wells Investment Bankers, LLC · broker-dealer Braymen, Lambert and Noel Securities, Ltd. (CRD 124902) · San Antonio, TexasSold in TX

Remarks in the notice

  • On the use of proceeds: “A portion of the proceeds will be used to pay the salaries to be paid to the person named in response toItem 3 above”

Signed by Paul Castella, President. Source: SEC Form D, newest notice filed Sep 5, 2012. Read the notice at the SEC.

equitySEC
Jul 2011$5 MNo. 3$2 to $10 million

BI02 Medical, Inc.: Raise no. 3, Jul 2011

Investors in this round

66 investors had bought by the notice of Aug 11, 2011: 66 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$5 M of $5 M offered; $1 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
No revenue
Sales commissions
$191,338
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions as estimates
The company
Corporation, incorporated in Texas

People named in the notice

  • Christopher Banas · Executive Officer, Director, Promoter
  • Luis Angel · Executive Officer, Director, Promoter
  • Paul Castella · Executive Officer, Director, Promoter
  • Alan Dean · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Karutz Flavin Wells Investment Bankers, LLC · broker-dealer Braymen, Lambert and Noel Securities, Ltd. (CRD 124902) · San Antonio, TexasSold in HI, TX, WA

Remarks in the notice

  • On the use of proceeds: “A portion of the proceeds will be used to pay the salaries to be paid to the persons named in response to Item 3 above”

Signed by Paul Castella, President. Source: SEC Form D, newest notice filed Aug 11, 2011. Read the notice at the SEC.

equitySEC
Mar 2010$7 MNo. 2$2 to $10 million

BI02 Medical, Inc.: Raise no. 2, Mar 2010

Investors in this round

57 investors had bought by the notice of May 4, 2010: 57 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$7 M of $8 M offered; $1 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
No revenue
Sales commissions
$273,933
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Texas

People named in the notice

  • Christopher Banas · Executive Officer, Director, Promoter
  • Luis Angel · Executive Officer, Director, Promoter
  • Paul Castella · Executive Officer, Director, Promoter
  • Alan Dean · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Karutz Flavin Wells Investment Bankers, LLC · broker-dealer BLN Securities Ltd (CRD 124902) · San Antonio, TexasSold in HI, TX, WA

Remarks in the notice

  • On the amounts: “$1,041,983.56 issued upon conversion of the principal and unaccrued unpaid interest under outstanding convertible promissory notes issued by the Issuer”
  • On the use of proceeds: “A portion of the proceeds will be used to pay the salaries to be paid to the persons named in response to Item 3 above”

Signed by Paul Castella, President. Source: SEC Form D and 1 amendment, newest notice filed May 4, 2010. Read the notice at the SEC.

equitySEC
Sep 2009$1 MNo. 1Under $2 million

BI02 Medical, Inc.: Raise no. 1, Sep 2009

Investors in this round

8 investors had bought by the notice of Apr 13, 2010: 8 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$1 M of $1 M offered
Smallest investment taken
no minimum stated
What was sold
debt, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
No revenue
Sales commissions
$20,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Texas

People named in the notice

  • Christopher Banas · Executive Officer, Director
  • Luis Angel · Executive Officer, Director
  • Paul Castella · Executive Officer, Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Karutz Flavin Wells Investment Bankers, LLC (CRD 124902) · San Antonio, TexasSold in TX

Remarks in the notice

  • On the use of proceeds: “Does not include amounts to be paid to executive officers of the Issuer in their capacity as employees of the Issuer.”

Signed by Paul Castella, President. Source: SEC Form D, newest notice filed Apr 13, 2010. Read the notice at the SEC.

debt, optionsSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • BI02 Medical, Inc. had revenue of up to $1 million when it filed its newest notice of a funding round (Mar 2017).

    SEC Form D (revenue range) · Mar 2017

  • Revenue range over time, as stated in its notices: no revenue in 2012; revenue of up to $1 million in 2014; revenue of up to $1 million in 2015; revenue of up to $1 million in 2017.

    SEC Form D (revenue range) · Mar 2017

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Mar 2017

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of BI02 Medical, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 7 rounds above had up to 66 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by BI02 Medical, Inc.
NameRoleNamed in
Christopher BanasExecutive officerMar 2017
Luis AngelExecutive officerMar 2017
Paul CastellaExecutive officerSep 2012
Alan DeanDirectorMar 2017
Christopher BanasDirectorMar 2017
John CreecyDirectorMar 2017
John ElwoodDirectorMar 2017
Luis AngelDirectorMar 2017
Paul CastellaDirectorMar 2017
Steven BaileyDirectorMar 2017
Christopher BanasPromoterAug 2011
Luis AngelPromoterAug 2011
Paul CastellaPromoterAug 2011